Global /China /Healthcare /Drug Manufacturers - General /002294

Shenzhen Salubris Pharmaceuticals Co., Ltd.

002294

• SHE: 002294 • Delayed

51.29CNY -1.2%

7.58 USD

As of 5 June 2026, Shenzhen Salubris Pharmaceuticals Co., Ltd. has a market cap of $8.55B USD, ranking #2516 globally and #418 in China. It ranks #185 in the Healthcare sector, and #69 in the Drug Manufacturers - General industry.

Global Rank

2516

Country Rank

418

Sector Rank

185

Industry Rank

Key Stats

Market Cap

$8.55BUSD

57.86B CNY

Enterprise Value

$8.33BUSD

56.39B CNY

Revenue (TTM)

$667.76MUSD

4.52B CNY

EBITDA (TTM)

$157.39MUSD

1.07B CNY

Net Income (TTM)

$99.96MUSD

676.45M CNY

EBITDA Margin

24%

Profit Margin

15%

PE Ratio

86.4

Forward PE

73.1

PS Ratio

12.8

PB Ratio

6.2

EV/EBITDA

52.3

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Jie Yan open_in_new

Employees

3,596

Founded

1998

Website

salubris.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.2%	-8.4%	-17%	8.7%	-9.8%	3.5%	26%	43%	44%

News

Markets

Exchange	Ticker	Price	Quotes
Shenzhen Stock Exchange (SHE / SZSE) MIC: XSHE PRIMARY	002294 深圳信立泰药业股份有限公司 Class A ISIN: CNE100000FW8 Shares Out.: Shares Outstanding: 1.115B¹ Shares Float: 442.414M² TV: TradingView: SZSE: 002294 SA: Stock Analysis: SHE: 002294 YF: Yahoo Finance: 002294.SZ GF: Google Finance: SHE: 002294 BA: Barron's: 002294 MS: Morningstar: XSHE: 002294	51.29 CNY	TV: TradingView: SZSE: 002294 SA: Stock Analysis: SHE: 002294 YF: Yahoo Finance: 002294.SZ GF: Google Finance: SHE: 002294 BA: Barron's: 002294 MS: Morningstar: XSHE: 002294

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices in China. The company is involved in the production and supply of pharmaceutical products in the fields of chronic diseases, including cardiovascular and cerebrovascular diseases, diabetes, oncology, osteoporosis, anti-infective diseases, and chronic kidney diseases. It also engages in the research and development, production, and sale of high-end interventional medical devices, such as cardiovascular and cerebrovascular, peripheral vascular, structural heart disease, electrophysiology, and cardiac rhythm management. The company was incorporated in 1998 and is headquartered in Shenzhen, China. Shenzhen Salubris Pharmaceuticals Co., Ltd. operates as a subsidiary of Salubris Pharmaceuticals Co., Ltd.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$53.92B 364.89B CNY 531%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.7B 336.36B CNY 481%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.52B 223.48B HKD 234%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 120%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.53B 111.89B CNY 93%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 87%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 9K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 6K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 4K%	97.4	United States
Roche Holding AG SIX: RO	$323.4B 256.25B CHF 4K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.25B 215.59B GBP 3K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$276.26B 218.9B CHF 3K%	20.5	Switzerland

chevron_leftBack